Abstract: The present invention relates to peptides comprising the amino acid sequence having a sequence identity of at least 70% with SEQ ID NO: 1, provided that said peptides do not have the amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 3, and that the cysteine at position 6 of SEQ ID NO: 1 remains unchanged. The invention also relates to a pharmaceutical composition thereof and to its uses in the treatment of tumours, in particular, in the treatment of cancer and metastases.

Abstract: An apparatus is described. The apparatus comprises a liquid dispenser comprising a liquid outlet, the liquid dispenser being configured to generate a droplet stream. The apparatus also comprises a first fluid flow device configured to generate a confinement fluid flow for confining a trajectory of the droplet stream therein, the first fluid flow device comprising an outlet arranged to allow the droplet stream to exit therefrom, wherein the fluid outlet is arranged within the confinement fluid flow device. Furthermore, the apparatus comprises a second fluid flow device configured to generate a reaction fluid flow for reacting with droplets in the droplet stream, wherein the outlet of the first fluid flow device is arranged within the second fluid flow device. A method is also described.

Abstract: Concentric flow focusing encapsulation devices and methods for production of microencapsulated droplets of a first core material surrounded by a second shell material include assessment of non-dimensional fluid dynamic parameters that are related to the characteristics of produced droplets. The parameters are specifically related to characteristics such as homogenous or non-homogenous modes of concentric droplet breakup, density distribution of various droplet sizes, and qualities such as monodispersity of droplets produced. By identifying control parameters in specific regions, control variables may be selected to produce droplets or particles with desired qualities.

Abstract: Concentric flow focusing encapsulation devices and methods for production of microencapsulated droplets of a first core material surrounded by a second shell material include assessment of non-dimensional fluid dynamic parameters that are related to the characteristics of produced droplets. The parameters are specifically related to characteristics such as homogenous or non-homogenous modes of concentric droplet breakup, density distribution of various droplet sizes, and qualities such as monodispersity of droplets produced. By identifying control parameters in specific regions, control variables may be selected to produce droplets or particles with desired qualities.

Abstract: An apparatus is described. The apparatus comprises a liquid dispenser comprising a liquid outlet, the liquid dispenser being configured to generate a droplet stream. The apparatus also comprises a first fluid flow device configured to generate a confinement fluid flow for confining a trajectory of the droplet stream therein, the first fluid flow device comprising an outlet arranged to allow the droplet stream to exit therefrom, wherein the fluid outlet is arranged within the confinement fluid flow device. Furthermore, the apparatus comprises a second fluid flow device configured to generate a reaction fluid flow for reacting with droplets in the droplet stream, wherein the outlet of the first fluid flow device is arranged within the second fluid flow device. A method is also described.

Abstract: An aqueous printing ink and coating composition contains colorant, one or more high molecular weight starches and one or more water soluble acrylic polymers or co-polymers.

Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula Ia.: wherein the substituent groups take various permitted meanings.

Abstract: This invention relates to antitumoral ecteinascidin derivatives that contain a fused ecteinascidin five ring system with a 1,4-bridge having the structure of formula (VIa) or (VIb) as described herein and compounds in which the —NH2 or —OH of the 1,4-bridge is derivatized, and related pharmaceutical compositions and methods. Such ecteinascidin derivatives include, but are not limited to, those compounds having formula (XVIIb): in which R1 and R4 together form a group of formula (VIa) or (VIb) as described herein, and R5, R7, R8, R14a, R14b, R15, and R21 are as defined herein.

Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula Ia.: wherein the substituent groups take various permitted meanings.

Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula (Ia) wherein the substituent groups take various permitted meanings.

Abstract: The invention relates to a method of obtaining micro- and nanometric polymeric particles in a controlled, reproducible manner. The aforementioned particles have a spherical shape and a very narrow, uniform size distribution. The invention comprises the use of an easy particle-forming method consisting in using hydrodynamic forces to focus a composite microjet formed by two concentric fluids and can be used in the encapsulation of fragile compounds of biological interest, from peptides and proteins to cells and micro-organisms.

Abstract: The invention relates to a method and device for obtaining micro and nanometric particles in a controlled, reproducible manner. The aforementioned particles have a spherical shape and a very narrow, uniform size distribution. More specifically, the invention relates to a novel method of forming emulsions and to the application thereof in micro and nanoencapsulation techniques involving the extraction/evaporation of the solvent. In particular, the invention relates to the encapsulation of the fluorescent compounds and the subsequent application thereof.

Abstract: This invention relates to antitumoral ecteinascidin derivatives.

Abstract: An aqueous printing ink and coating composition contains colorant, one or more high molecular weight starches and one or more water soluble acrylic polymers or co-polymers.

Abstract: This invention relates to compounds of the formula: wherein: the substituent groups defined by R1, R2 are each independently selected of H, C(?O)R?, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl; each of the R? groups is independently selected from the group consisting of H; OH; NO2; NH2; SH; CN; halogen; ?O; C(?O)H; C(?O)CH3; CO2H; or C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl, each of which, independently, may be substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, nitro, azido; alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, aryloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aminoalkyl, carbocylic aryl having 6 or more carbons, and aralkyl; X2 is OX1 or N(X1)2 wherein each X1 is independently H, C(?O)R? where R? is as defined, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, aryl, alkoxy, heterocyclyl, or two X1 groups together form a cyclic substituent on the nitrogen atom, or X1 is SO2CH3 when X2 is OX1, or N(X1)2 is NHCOalk

Abstract: This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule.

Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula (Ia) wherein the substituent groups take various permitted meanings.

Abstract: Compounds having a fused ecteinascidin five ring system with a 1,4 bridge having the structure of formula (VIa or VIb) and compounds in which the —NH2 or —OH of the 1,4 bridge is derivatised are disclosed. Such compounds are useful in the treatment of tumours.